US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0160-5 D-0345-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0150-5 D-0344-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0145-5 D-0343-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0135-5 D-0342-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0125-5 D-0341-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0120-5 D-0340-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0117-5 D-0339-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0115-5 D-0338-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0113-5 D-0337-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0112-5 D-0336-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0110-5 D-0335-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0155-5 D-0334-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0140-5 D-0333-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0130-5 D-0332-2023
Class II · Moderate risk Terminated

Tirosint - Sol

Reason Subpotent Drug

Ibsa Pharma INC NDC 71858-0105-5 D-0331-2023
Class III · Low risk Ongoing

Atropine Sulfate Ophthalmic Solution

Reason Failed Stability Specifications: Out of specification test results for viscosity was identified at the 12M stability timepoint.

Akorn, Inc. D-0265-2023
Class II · Moderate risk Terminated

Verapamil Hydrochloride Extended-Release Tablets

Reason Failed Dissolution Specification: Out of specification dissolution results at time point zero. The OOS was above specified values.

Amerisource Health Services LLC D-0436-2023
Class III · Low risk Terminated

Clobetasol propionate Cream USP

Reason Subpotent Drug: Low assay result observed during long-term stability testing.

Lupin Pharmaceuticals Inc. NDC 68180-956-03 D-0174-2023
Class II · Moderate risk Terminated

Ohm Sanitizer Spray

Reason CGMP Deviations: FDA analysis found product to contain acetaldehyde and acetal above specification limits.

Urban Electric Power D-0264-2023
Class II · Moderate risk Terminated

Ohm Hand Sanitizer

Reason CGMP Deviations: FDA analysis found product to contain acetaldehyde and acetal above specification limits.

Urban Electric Power D-0263-2023
Class II · Moderate risk Ongoing

Hand Sanitizer

Reason CGMP Deviations: Voluntary recall of all hand sanitizer distributed after March 31, 2022, due to FDA issued guidance to cease placing hand sanitizer product, produced under temporary approval, into the market after March 31, 2022.

Fisher Scientific Co., LLC D-0164-2023
Class II · Moderate risk Ongoing

Hand Sanitizer

Reason CGMP Deviations: Voluntary recall of all hand sanitizer distributed after March 31, 2022, due to FDA issued guidance to cease placing hand sanitizer product, produced under temporary approval, into the market after March 31, 2022.

Fisher Scientific Co., LLC D-0163-2023
Class II · Moderate risk Terminated

Allopurinol Tablets 100mg

Reason Presence of Foreign Substance: manufacturer recalled this re-packaged product due to reports of a small piece of green plastic embedded in the crack towards the edge of the tablet.

Preferred Pharmaceuticals, Inc. D-0173-2023
Class II · Moderate risk Terminated

Diltiazem Hydrochloride Extended-Release Capsules

Reason Failed Impurity (Deacetyl Diltiazem Hydrochloride) specification during stability testing and failed dissolution testing at FDA laboratory.

Sun Pharmaceutical Industries INC NDC 47335-679-81 D-0262-2023